159 related articles for article (PubMed ID: 37267808)
1. Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping.
Royer B; Launay M; Ciccolini J; Derain L; Parant F; Thomas F; Guitton J
ESMO Open; 2023 Jun; 8(3):101577. PubMed ID: 37267808
[TBL] [Abstract][Full Text] [Related]
2. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
[TBL] [Abstract][Full Text] [Related]
3. Renal impairment and DPD testing: Watch out for false-positive results!
Carriat L; Quaranta S; Solas C; Rony M; Ciccolini J
Br J Clin Pharmacol; 2022 Nov; 88(11):4928-4932. PubMed ID: 35939355
[TBL] [Abstract][Full Text] [Related]
4. Screening for dihydropyrimidine dehydrogenase deficiency by measuring uracilemia in chronic kidney disease patients is associated with a high rate of false positives.
Narjoz C; Nadour Z; Zaanan A; Taieb J; Loriot MA; Pallet N
Clin Chim Acta; 2023 Mar; 543():117326. PubMed ID: 37011867
[TBL] [Abstract][Full Text] [Related]
5. Renal impairment and abnormal liver function tests in pre-therapeutic phenotype-based DPD deficiency screening using uracilemia: a comprehensive population-based study in 1138 patients.
Callon S; Brugel M; Botsen D; Royer B; Slimano F; Feliu C; Gozalo C; Konecki C; Devie B; Carlier C; Daire V; Laurés N; Perrier M; Djerada Z; Bouché O
Ther Adv Med Oncol; 2023; 15():17588359221148536. PubMed ID: 36643657
[TBL] [Abstract][Full Text] [Related]
6. Pretherapeutic screening for Dihydropyrimidine deshydrogenase deficiency in measuring uracilemia in dialysis patients leads to a high rate of falsely positive results.
Gaible C; Narjoz C; Loriot MA; Roueff S; Pallet N
Cancer Chemother Pharmacol; 2021 Dec; 88(6):1049-1053. PubMed ID: 34515833
[TBL] [Abstract][Full Text] [Related]
7. Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature.
Hodroj K; Barthelemy D; Lega JC; Grenet G; Gagnieu MC; Walter T; Guitton J; Payen-Gay L
ESMO Open; 2021 Jun; 6(3):100125. PubMed ID: 33895696
[TBL] [Abstract][Full Text] [Related]
8. Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency.
Etienne-Grimaldi MC; Pallet N; Boige V; Ciccolini J; Chouchana L; Barin-Le Guellec C; Zaanan A; Narjoz C; Taieb J; Thomas F; Loriot MA;
Eur J Cancer; 2023 Mar; 181():3-17. PubMed ID: 36621118
[TBL] [Abstract][Full Text] [Related]
9. Impact of Guidelines Regarding Dihydropyrimidine Dehydrogenase (DPD) Deficiency Screening Using Uracil-Based Phenotyping on the Reduction of Severe Side Effect of 5-Fluorouracil-Based Chemotherapy: A Propension Score Analysis.
Laures N; Konecki C; Brugel M; Giffard AL; Abdelli N; Botsen D; Carlier C; Gozalo C; Feliu C; Slimano F; Djerada Z; Bouché O
Pharmaceutics; 2022 Oct; 14(10):. PubMed ID: 36297556
[TBL] [Abstract][Full Text] [Related]
10. New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine.
García-González X; Kaczmarczyk B; Abarca-Zabalía J; Thomas F; García-Alfonso P; Robles L; Pachón V; Vaz Á; Salvador-Martín S; Sanjurjo-Sáez M; López-Fernández LA
Cancer Chemother Pharmacol; 2020 Jul; 86(1):45-54. PubMed ID: 32529295
[TBL] [Abstract][Full Text] [Related]
11. Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study.
de With M; Knikman J; de Man FM; Lunenburg CATC; Henricks LM; van Kuilenburg ABP; Maring JG; van Staveren MC; de Vries N; Rosing H; Beijnen JH; Pluim D; Modak A; Imholz ALT; van Schaik RHN; Schellens JHM; Gelderblom H; Cats A; Guchelaar HJ; Mathijssen RHJ; Swen JJ; Meulendijks D
Clin Pharmacol Ther; 2022 Jul; 112(1):62-68. PubMed ID: 35397172
[TBL] [Abstract][Full Text] [Related]
12. Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency.
Maillard M; Launay M; Royer B; Guitton J; Gautier-Veyret E; Broutin S; Tron C; Le Louedec F; Ciccolini J; Richard D; Alarcan H; Haufroid V; Tafzi N; Schmitt A; Etienne-Grimaldi MC; Narjoz C; Thomas F;
Br J Clin Pharmacol; 2023 Feb; 89(2):762-772. PubMed ID: 36104927
[TBL] [Abstract][Full Text] [Related]
13. Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe.
de With M; Sadlon A; Cecchin E; Haufroid V; Thomas F; Joerger M; van Schaik RHN; Mathijssen RHJ; Largiadèr CR;
ESMO Open; 2023 Apr; 8(2):101197. PubMed ID: 36989883
[TBL] [Abstract][Full Text] [Related]
14. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.
Henricks LM; Siemerink EJM; Rosing H; Meijer J; Goorden SMI; Polstra AM; Zoetekouw L; Cats A; Schellens JHM; van Kuilenburg ABP
Int J Cancer; 2018 Jan; 142(2):424-430. PubMed ID: 28929491
[TBL] [Abstract][Full Text] [Related]
15. Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency.
Gbeto CC; Quaranta S; Mari R; Fanciullino R; Roche C; Nahon S; Solas C; Ouafik L; Lacarelle B; Allegre T; Ciccolini J
Pharmacogenomics; 2019 Aug; 20(13):931-938. PubMed ID: 31486738
[TBL] [Abstract][Full Text] [Related]
16. Implementation and clinical benefit of DPYD genotyping in a Danish cancer population.
Paulsen NH; Pfeiffer P; Ewertz M; Fruekilde PBN; Feddersen S; Holm HS; Bergmann TK; Qvortrup C; Damkier P
ESMO Open; 2023 Feb; 8(1):100782. PubMed ID: 36791638
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency.
Pallet N; Hamdane S; Garinet S; Blons H; Zaanan A; Paillaud E; Taieb J; Laprevote O; Loriot MA; Narjoz C
Br J Cancer; 2020 Sep; 123(5):811-818. PubMed ID: 32595208
[TBL] [Abstract][Full Text] [Related]
18. DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview.
Paulsen NH; Vojdeman F; Andersen SE; Bergmann TK; Ewertz M; Plomgaard P; Hansen MR; Esbech PS; Pfeiffer P; Qvortrup C; Damkier P
Basic Clin Pharmacol Toxicol; 2022 Nov; 131(5):325-346. PubMed ID: 35997509
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
Meulendijks D; Henricks LM; Jacobs BAW; Aliev A; Deenen MJ; de Vries N; Rosing H; van Werkhoven E; de Boer A; Beijnen JH; Mandigers CMPW; Soesan M; Cats A; Schellens JHM
Br J Cancer; 2017 May; 116(11):1415-1424. PubMed ID: 28427087
[TBL] [Abstract][Full Text] [Related]
20. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
Ogura K
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
